Dr Benjamin Ebert

Dr. Benjamin Ebert is the Chair of Medical Oncology at the Dana-Farber Cancer Institute, the George P. Canellos, MD and Jean S. Canellos Professor of Medicine at Harvard Medical School, a Howard Hughes Medical Institute Investigator, and an Institute Member of the Broad Institute. The Ebert laboratory focuses on the molecular basis and treatment of hematologic malignancies and its non-malignant precursor conditions, with a particular focus on myelodysplastic syndromes (MDS) and clonal hematopoiesis.  The Ebert laboratory demonstrated that lenalidomide, a derivative of thalidomide, binds the CRL4-CRBN E3 ubiquitin ligase and induces degradation of specific substrates.  Subsequent research has examined novel mechanisms of drug-induced protein degradation that expand the spectrum of protein substrates that can be targeted pharmacologically. 

Dr. Ebert received a bachelor's degree from Williams College and a doctorate from Oxford University.  He completed an M.D. from Harvard Medical School, a residency in internal medicine at Massachusetts General Hospital, and a fellowship in hematology/oncology at the Dana-Farber Cancer Institute.  He is an elected member of the National Academy of Medicine, the American Academy of Arts and Sciences, the American Society for Clinical Investigation and the Association of American Physicians. He served as president of the American Society for Clinical Investigation. His awards include the Meyenburg Prize for Cancer Research, the Sjöberg Prize, and the Korsmeyer Award.